CMPS COMPASS Pathways: Enterprise Value-to-Revenue Multiple

Public company logo of COMPASS Pathways (CMPS)

COMPASS Pathways plc (CMPS) innovations in depression treatment remain in demand regardless of economic cycles. The enterprise value-to-annual revenue multiple on the GURU.Markets daily chart reflects current dynamics, where the 0.00 level captures recent values. However, the biotech's venture profile leaves the asset vulnerable to macro shocks, and high clinical costs necessitate continuous external financing until sales commence.

COMPASS Pathways PLC (CMPS) Enterprise Value-to-Revenue Ratio: for the period 11/23/2025 - 11/19/2026

CMPS (COMPASS Corp): analytical breakdowns and indicator data

- market value and analyst target forecast:
- company stock capitalization data:
Initial company analysis:CMPS (COMPASS Pathways)
Mass-produced product of Compass Pathways

This indicator determines the investment attractiveness of an asset through the lens of the business's market value. The metric compares the total enterprise value, including debt, with sales volume, eliminating the impact of credit load on the valuation. By analyzing the ratio of business value to annual revenue, an investor can identify the actual premium for growth potential. For COMPASS Pathways plc (CMPS), this figure reflects market expectations for the commercialization of COMP360 therapy. Future sales of psilocybin-based drugs will be the key factor in revising this fundamental valuation.